Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublocade vs Suboxone SL in Opioid Use Disorder
NCT03744663Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Wake Forest University Health Sciences. Planned start Jun 2022; status: withdrawn.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03744663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744663.